ESMO Asia 2025 | Professor George Lau: HR 0.60！STRIDE regimen Chinese population data impressively unveiled, dual immunotherapy efficacy significantly

ESMO Asia 2025 | Professor George Lau: HR 0.60！STRIDE regimen Chinese population data impressively unveiled, dual immunotherapy efficacy significantly

2025.12.11
From December 5 to 7, 2025, the highly anticipated European Society for Medical Oncology Asia Congress (ESMO Asia 2025) was grandly held in Singapore. During the Mini Oral Session: Gastrointestinal Tumours, Professor George Lau, Chairman of the Hong Kong Humanity Medical Group and Director of the Humanity Medical Clinical Research CenterSenior Consultant in Gastroenterology and Hepatology, Humanity and Health Medical Center, Principal Investigator of the Humanity and Health Clinical Trial Center, as well as a physician Honorary Professor and Senior Consultant at Zhongshan Hospital Affiliated to Fudan University, was invited to deliver an oral presentation. For the first time, he shared the research data on the treatment of Asian patients with unresectable hepatocellular carcinoma (HCC) using Tremelimumab in combination with Durvalumab. This study is based on a sample that more closely reflects the epidemiological characteristics and disease spectrum of Asian patients, providing high-quality evidence-based medical evidence with targeted relevance. It lays a solid foundation for optimizing and advancing the individualization and precision of liver cancer treatment strategies in this region.
ASH China Voice | Jia Wei’s Team Presents Seven Studies at ASH 2025, Advancing Multi-Dimensional Exploration of Therapeutic Bottlenecks in Hematologic

ASH China Voice | Jia Wei’s Team Presents Seven Studies at ASH 2025, Advancing Multi-Dimensional Exploration of Therapeutic Bottlenecks in Hematologic

2025.12.10
From December 6–9, 2025, the 67th American Society of Hematology (ASH) Annual Meeting was held in Orlando. As the world’s most influential and comprehensive academic event in hematology, ASH annually gathers tens of thousands of experts to present breakthroughs spanning basic research to clinical innovation. This year, the team led by Professor Jia Wei of Tongji Hospital, Huazhong University of Science and Technology, had seven studies accepted—one oral presentation and six posters—covering CAR-T therapy, multi-omics analysis and immunotherapy. These studies collectively illustrate a full-spectrum innovation pipeline from mechanistic discovery to translational clinical application. Hematology Frontier summarizes the key findings below and presents Professor Wei’s commentary on their broader significance.
ASH China Voice | Wei Zhang, MD: Novel Loop-Structured CD19/CD22 Dual-Target CAR-T Therapy Brings Breakthrough Hope for Refractory/Relapsed B-NHL

ASH China Voice | Wei Zhang, MD: Novel Loop-Structured CD19/CD22 Dual-Target CAR-T Therapy Brings Breakthrough Hope for Refractory/Relapsed B-NHL

2025.12.10
From December 6–9, 2025, the 67th American Society of Hematology (ASH) Annual Meeting convened in Orlando, attracting tens of thousands of hematology experts worldwide. As the most influential international conference in the field, ASH showcases cutting-edge advances and breakthrough clinical findings each year. At this year’s meeting, an innovative study led by Dr. Wei Zhang of Lu Daopei Hospital was selected for poster presentation. The study introduced a novel loop-structured CD19/CD22 dual-target CAR-T therapy designed to overcome antigen escape and relapse—two major obstacles in B-cell malignancies. This approach offers renewed therapeutic hope for patients with refractory or relapsed B-cell non-Hodgkin lymphoma (B-NHL). We invited Dr. Zhang to elaborate on this research.
ESMO25 Highlight | Insights from Dr. Darren M. Poon

ESMO25 Highlight | Insights from Dr. Darren M. Poon

2025.12.10
At the recent ESMO Asia 2025 Congress, a study by Professor Darren Poon's team at the Hong Kong Comprehensive Oncology Centre was selected, bringing a new precision medicine strategy to patients with advanced prostate cancer. Oncology Frontier- UroStream invited Professor Poon to share his insights on the clinical value and future prospects of liquid biopsy for Chinese patients with androgen receptor ligand binding domain-mutated prostate cancer. #ESMOAsia2025 #prostatecancer #precisionmedicine
SIBCS 2025丨Feng Jin: China’s Breast Cancer Clinical Research Enters a New Era of Systematic Innovation Driven by Precision Medicine and Domestic Drug Development 

SIBCS 2025丨Feng Jin: China’s Breast Cancer Clinical Research Enters a New Era of Systematic Innovation Driven by Precision Medicine and Domestic Drug Development 

2025.12.09
The 20th Shanghai International Breast Cancer Symposium (SIBCS), jointly organized by the Shanghai Anti-Cancer Association and the Breast Cancer Committee of the China Anti-Cancer Association, was recently held in Shanghai. Under the theme “20 Years of Progress, a Future of Continuity”, the forum brought together leading experts from China and abroad to reflect on two decades of advances in breast cancer diagnosis and treatment in China. During the “Year in Review” session, Professor Feng Jin of the First Hospital of China Medical University delivered a presentation titled “Key Clinical Trial Achievements in Chinese Breast Cancer Research.” Oncology Frontier invited Professor Jin for an in-depth discussion on China’s breakthrough clinical evidence, its global impact, and China’s future developmental directions in breast cancer research.